Use of PULSAR (personalized ultra-fractionated stereotactic adaptive radiotherapy) as consolidation with immune checkpoint inhibition in the treatment of pediatric metastatic melanoma
Publication
, Journal Article
McCarty, KL; Watt, T; Dan, TD; Timmerman, RD; Kumar, KA
Published in: Radiation Oncology
August 21, 2025
Duke Scholars
Published In
Radiation Oncology
DOI
EISSN
1748-717X
Publication Date
August 21, 2025
Volume
20
Issue
1
Publisher
Springer Science and Business Media LLC
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
McCarty, K. L., Watt, T., Dan, T. D., Timmerman, R. D., & Kumar, K. A. (2025). Use of PULSAR (personalized ultra-fractionated stereotactic adaptive radiotherapy) as consolidation with immune checkpoint inhibition in the treatment of pediatric metastatic melanoma. Radiation Oncology, 20(1). https://doi.org/10.1186/s13014-025-02691-y
McCarty, Kyra L., Tanya Watt, Tu D. Dan, Robert D. Timmerman, and Kiran A. Kumar. “Use of PULSAR (personalized ultra-fractionated stereotactic adaptive radiotherapy) as consolidation with immune checkpoint inhibition in the treatment of pediatric metastatic melanoma.” Radiation Oncology 20, no. 1 (August 21, 2025). https://doi.org/10.1186/s13014-025-02691-y.
McCarty KL, Watt T, Dan TD, Timmerman RD, Kumar KA. Use of PULSAR (personalized ultra-fractionated stereotactic adaptive radiotherapy) as consolidation with immune checkpoint inhibition in the treatment of pediatric metastatic melanoma. Radiation Oncology. 2025 Aug 21;20(1).
McCarty, Kyra L., et al. “Use of PULSAR (personalized ultra-fractionated stereotactic adaptive radiotherapy) as consolidation with immune checkpoint inhibition in the treatment of pediatric metastatic melanoma.” Radiation Oncology, vol. 20, no. 1, Springer Science and Business Media LLC, Aug. 2025. Crossref, doi:10.1186/s13014-025-02691-y.
McCarty KL, Watt T, Dan TD, Timmerman RD, Kumar KA. Use of PULSAR (personalized ultra-fractionated stereotactic adaptive radiotherapy) as consolidation with immune checkpoint inhibition in the treatment of pediatric metastatic melanoma. Radiation Oncology. Springer Science and Business Media LLC; 2025 Aug 21;20(1).
Published In
Radiation Oncology
DOI
EISSN
1748-717X
Publication Date
August 21, 2025
Volume
20
Issue
1
Publisher
Springer Science and Business Media LLC
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis